FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and concerns methods of monitoring efficiency of anticancer treatment of non-small cell lung cancer. Method involves determining expression levels of microRNA markers in patient's peripheral blood after surgical management, wherein levels of microRNA-19b, microRNA-125b and combination of microRNA-125b/microRNA-19b 2 weeks, 3 and 6 months, 1 and 2 years after treatment. When obtaining linear model of microRNA expression levels changing dynamics, characterized by gradual increase of microRNA-19b, reduction of microRNA-125b and combination of microRNA-125b/microRNA-19b relative to initial values, disease progression is determined, and when obtaining quadratic model of microRNA expression levels changing dynamics, characterized by alternation of increasing or decreasing of expression levels of analyzed microRNA decreased or increased analogous values relative to initial values, remission is determined.
EFFECT: invention provides more accurate early diagnosis of progression of non-small cell lung cancer due to regular comparative analysis of end sections of microRNA expression during dynamic observation.
1 cl, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ESTIMATING RISK OF PROGRESSING NON-SMALL-CELL LUNG CANCER FOLLOWING SURGICAL MANAGEMENT | 2011 |
|
RU2472161C1 |
| METHOD FOR PREDICTION OF RISK OF HEMATOGENOUS METASTASES IN NON-SMALL-CELL LUNG CANCER PATIENTS AFTER OPERATION | 2019 |
|
RU2733160C1 |
| METHOD FOR PREDICTING AN UNFAVORABLE OUTCOME IN NON-SMALL-CELL LUNG CANCER | 2019 |
|
RU2696872C1 |
| METHOD FOR COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER IB-III STAGE USING PERSONALIZED PERIOPERATIVE CHEMOTHERAPY | 2019 |
|
RU2706718C1 |
| METHOD OF PERSONALIZED COMBINED TREATMENT OF NON-CELL LUNG CANCER 1B-111 STAGE ON THE BASIS OF ESTIMATION OF THE LEVELS OF EXPRESSION OF MONORESISTENCE GENES | 2017 |
|
RU2665133C1 |
| METHOD FOR PREDICTION OF ONSET OF HEMATOGENOUS METASTASES ACCOMPANYING SQUAMOUS CELL LUNG CANCER | 2012 |
|
RU2489718C1 |
| METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY | 2015 |
|
RU2593342C1 |
| METHOD FOR PERSONALIZED COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER STAGE II-III | 2022 |
|
RU2784958C1 |
| ANALYTICAL SYSTEM FOR DIAGNOSING LUNG CANCER USING FREE AND CIRCULATING MICRO-RNAS ASSOCIATED WITH BLOOD CELLS | 2020 |
|
RU2755651C1 |
| METHOD OF COMBINED TREATMENT OF NON-SMALL CELL CANCER OF LUNG OF III STAGE | 2007 |
|
RU2340336C1 |
